Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[67Cu]Cu-rhPSMA-10.1 is a **radiohybrid prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical** labeled with copper-67, designed for targeted radionuclide therapy of PSMA-expressing tumors, such as prostate cancer and glioblastoma multiforme (GBM). It delivers cytotoxic radiation selectively to PSMA-positive cancer cells via the high-affinity PSMA-targeting ligand rhPSMA-10.1, enabling targeted destruction of malignant tissue while sparing healthy cells. Its theranostic potential is supported by PET-based dosimetry and SPECT imaging, and it is currently in early clinical/late preclinical evaluation[3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [67Cu]Cu-rhPSMA-10.1.